Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th
- WARREN, N.J., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it will hold a virtual investor day on September 27, 2024 at 8:00 am ET to discuss the Company's pipeline updates, inclusive of Anaphylm™ (epinephrine) Sublingual Film and AQST-108 (epinephrine) Topical Gel, both candidate products emerging from the Company's Adrenaverse™ epinephrine prodrug platform. The event will include presentations by members of the Aquestive management team and by a distinguished key opinion leader J. David Farrar, PhD, Associate Professor, Immunology/Molecular Biology, UT Southwestern Medical Center.
- 09/09/2024
|
Aquestive Therapeutics: Bullish Roadmap After Q2 Earnings
- Aquestive Therapeutics Q2 earnings report showed significant beats in EPS and revenue, with a 52% year-over-year revenue increase. The company reported improved operational efficiency and profitability, with a positive non-GAAP adjusted EBITDA of $1.8M and $89.9M in cash, extending their cash runway into 2026. Aquestive provided updates on Anaphylm's progress towards an NDA submission in early 2025, as well as advancements in their Adrenaverse platform and Libervant's market access.
- 08/22/2024
|
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
- WARREN, N.J., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in two upcoming investor conferences in September 2024 as follows:
- 08/22/2024
|
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
- Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST's robust R&D pipeline, with analysts giving outperform rating and price target increase to $15. AQST recorded significant revenue growth in Q2 2024, with a cash balance of $89.87 million and sufficient funds until the end of 2026.
- 08/20/2024
|
Aquestive Therapeutics Inc. (AQST) Q2 2024 Earnings Call Transcript
- Aquestive Therapeutics Inc. (NASDAQ:AQST ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Carl Kraus - Chief Medical Officer Stephen Wargacki - Chief Science Officer Sherry Korczynski - Senior Vice President of Sales and Marketing Conference Call Participants Roanna Ruiz - Leerink Partners David Amsellem - Piper Sandler François Brisebois - Oppenheimer Raghuram Selvaraju - H.C. Wainwright Thomas Flaten - Lake Street Securities Jason Butler - Citizens JMP Gary Nachman - Raymond James James Molloy - Alliance Global Partners Operator Good morning, and welcome to the Aquestive Therapeutics Second Quarter 2024 Conference Call.
- 08/07/2024
|
Aquestive Therapeutics (AQST) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
- Although the revenue and EPS for Aquestive Therapeutics (AQST) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
- 08/06/2024
|
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.10 per share a year ago.
- 08/06/2024
|
Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
- WARREN, N.J., Aug. 06, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST) ("Aquestive" or the "Company"), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, reported financial results for the second quarter, which ended June 30, 2024, and provided an update on recent developments in its business.
- 08/06/2024
|
Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study
- WARREN, N.J., July 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline PK data from the self-administration study of Anaphylm™ (epinephrine) Sublingual Film. Anaphylm has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the United States Food and Drug Administration (FDA).
- 07/25/2024
|
Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET
- WARREN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the second quarter ended June 30, 2024 and provide an update on recent developments in its business after market close on Tuesday, August 6, 2024.
- 07/23/2024
|
New Strong Sell Stocks for July 16th
- ALB, AAL and AQST have been added to the Zacks Rank #5 (Strong Sell) List on July 16, 2024.
- 07/16/2024
|
New Strong Sell Stocks for July 11th
- AQST, CENTA and RAMP have been added to the Zacks Rank #5 (Strong Sell) List on July 11, 2024.
- 07/11/2024
|
Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism
- WARREN, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the Aquestive management team will participate in the Leerink Partners Therapeutics Forum: I&I and Metabolism and host investor meetings on July 9, 2024. The forum will include panels exploring key therapeutic themes across the fields of immunology and inflammation (I&I) and metabolism.
- 06/27/2024
|
Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities
- WARREN, N.J., June 03, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced it has strengthened its leadership team with three executive appointments ahead of the anticipated launch of Anaphylm™ (epinephrine) Sublingual Film, the Company's epinephrine prodrug product candidate that has the potential to be the first and only non-invasive, orally delivered epinephrine for the treatment of severe life-threatening allergic reactions, including anaphylaxis, if approved by the U.S. Food and Drug Administration (FDA). Sherry Korczynski joined the Aquestive leadership team as Senior Vice President, Sales and Marketing. Cassie Jung was promoted to Chief Operating Officer, and Stephen Wargacki, Ph.D., was named Chief Science Officer.
- 06/03/2024
|
5 Small Drug Stocks to Buy From a Recovering Industry
- Innovation is expected to continue to drive the growth of the Zacks Medical-Drugs industry. HRTX, BVS, AQST, ACRV and CRDL may prove to be good additions to one's portfolio.
- 05/24/2024
|
Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference
- WARREN, N.J., May 09, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, announced today that the management team will participate in The Citizens JMP Life Sciences Conference on May 13, 2024.
- 05/09/2024
|
Aquestive Therapeutics, Inc. (AQST) Q1 2024 Earnings Call Transcript
- Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q1 2024 Earnings Conference Call May 8, 2024 8:00 AM ET Company Participants Bennett Watson – ICR Westwicke Investor Relations Dan Barber – Chief Executive Officer and President Ernie Toth – Chief Financial Officer Stephen Wargacki – Chief Science Officer Conference Call Participants David Amsellem – Piper Sandler Francois Brisebois – Oppenheimer Ram Selvaraju – H.C. Wainwright Gary Nachman – Raymond James Thomas Flaten – Lake Street Capital Markets Operator Good morning, and welcome to Aquestive Therapeutics First Quarter 2024 Conference Call.
- 05/08/2024
|
Compared to Estimates, Aquestive Therapeutics (AQST) Q1 Earnings: A Look at Key Metrics
- The headline numbers for Aquestive Therapeutics (AQST) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
- 05/07/2024
|
Aquestive Therapeutics (AQST) Reports Q1 Loss, Misses Revenue Estimates
- Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to earnings of $0.11 per share a year ago.
- 05/07/2024
|
Aquestive Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- WARREN, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, reported financial results for the first quarter, which ended March 31, 2024, and provided an update on recent developments in its business.
- 05/07/2024
|
Analysts Estimate Aquestive Therapeutics (AQST) to Report a Decline in Earnings: What to Look Out for
- Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 04/30/2024
|
Aquestive Therapeutics to Present Crossover Study Data for Libervant™ (diazepam) Buccal Film at 76th Annual Meeting of the American Academy of Neurology
- WARREN, N.J., April 12, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the crossover study for the Company's product candidate, Libervant™ (diazepam) Buccal Film for treatment of children with epilepsy aged two to five, will be presented at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver from April 13 to 18, offering both in-person attendance and live online participation in a hybrid format.
- 04/12/2024
|
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
- Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
- 04/09/2024
|
Aquestive Therapeutics (AQST) Ascends While Market Falls: Some Facts to Note
- Aquestive Therapeutics (AQST) concluded the recent trading session at $4.14, signifying a +0.24% move from its prior day's close.
- 04/02/2024
|
Aquestive Therapeutics Announces Closing of Underwritten Public Offering of Common Stock
- WARREN, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the closing of its previously announced underwritten public offering of 16,666,667 shares of its common stock at the public offering price of $4.50 per share. At closing, the aggregate gross proceeds of the offering to Aquestive, before deducting underwriting discounts and commissions and other offering expenses paid by Aquestive, were approximately $75.0 million.
- 03/25/2024
|
Aquestive Therapeutics (AQST) Flat As Market Sinks: What You Should Know
- In the closing of the recent trading day, Aquestive Therapeutics (AQST) stood at $4.38, denoting no change from the preceding trading day.
- 03/22/2024
|
Why Is Aquestive Therapeutics (AQST) Stock Down 14% Today?
- Aquestive Therapeutics (NASDAQ: AQST ) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares. Aquestive Therapeutics is selling 16,666,667 shares of AQST stock for $4.50 each in this public offering.
- 03/20/2024
|
Aquestive Therapeutics Announces Pricing of $75 Million Underwritten Public Offering of Common Stock
- WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (“Aquestive” or the “Company”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced the pricing of an underwritten public offering of 16,666,667 shares of its common stock at a public offering price of $4.50 per share. The gross proceeds of the offering to Aquestive, before deducting the underwriting discounts and commissions and other offering expenses payable by Aquestive, are expected to be approximately $75.0 million. The Company intends to use the net proceeds received from the offering, together with the Company's existing cash and cash equivalents, primarily to advance the development and commercialization of its product pipeline, including Anaphylm™ (epinephrine) Sublingual Film for the treatment of severe life-threatening allergic reactions, including anaphylaxis, and Libervant™ (diazepam) Buccal Film for the treatment of seizure clusters in epilepsy patients aged two to five, and for working capital, capital expenditures and general corporate purposes. In addition, Aquestive has granted the underwriters a 30-day option to purchase up to an additional 2,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. All of the securities are to be sold by the Company. The offering is expected to close on or about March 22, 2024, subject to satisfaction of customary closing conditions.
- 03/19/2024
|
Aquestive Therapeutics Announces Proposed Public Offering of Common Stock
- WARREN, N.J., March 19, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. In addition, Aquestive expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering. All of the securities in the public offering are being offered by Aquestive. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- 03/19/2024
|
Aquestive (AQST) Up as Anaphylm Pivotal Study Meets Goals
- Aquestive's (AQST) stock rises after meeting primary and secondary goals in the pivotal study of Anaphylm Sublingual Film to treat severe allergic reactions, including anaphylaxis.
- 03/18/2024
|
Strength Seen in Aquestive Therapeutics (AQST): Can Its 16.0% Jump Turn into More Strength?
- Aquestive Therapeutics (AQST) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
- 03/18/2024
|
Aquestive Therapeutics Announces Pivotal Study for Anaphylm™ (epinephrine) Sublingual Film Successfully Meets Primary and Secondary Endpoints and Provides Clinical Development Update Following FDA Meeting
- WARREN, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today released positive topline clinical data from its Phase 3 pivotal pharmacokinetic (PK) clinical study of Anaphylm™ (epinephrine) Sublingual Film and findings from the FDA Type C meeting. Anaphylm is the Company's first and only orally administered epinephrine prodrug product candidate under development for the treatment of severe life-threatening allergic reactions, including anaphylaxis.
- 03/14/2024
|
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.23 per share a year ago.
- 03/05/2024
|
Aquestive Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
- WARREN, N.J., March 05, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a progress update on the key 2024 objectives previously outlined by the Company.
- 03/05/2024
|
Wall Street Bulls Look Optimistic About Aquestive Therapeutics (AQST): Should You Buy?
- Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
- 03/04/2024
|
Aquestive Therapeutics (AQST) Outperforms Broader Market: What You Need to Know
- Aquestive Therapeutics (AQST) closed the most recent trading day at $3.67, moving +0.55% from the previous trading session.
- 02/29/2024
|
Aquestive (AQST) to Report Q4 Earnings: Here's What to Expect
- Investor focus is likely to be on Aquestive Therapeutics' (AQST) updates regarding key pipeline candidate, Anaphylm Sublingual Film, on the fourth-quarter 2023 earnings call.
- 02/21/2024
|
Aquestive Therapeutics to Report Fourth Quarter 2023 Financial Results and Recent Business Highlights on March 5 and Host Conference Call on March 6 at 8:00 a.m. ET
- WARREN, N.J., Feb. 21, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that it will report results for the fourth quarter ended December 31, 2023 and provide an update on recent developments in its business after market close on Tuesday, March 5, 2024.
- 02/21/2024
|
Aquestive Therapeutics (AQST) Registers a Bigger Fall Than the Market: Important Facts to Note
- In the latest trading session, Aquestive Therapeutics (AQST) closed at $2.65, marking a -1.67% move from the previous day.
- 02/20/2024
|
Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data at the 2024 AAAAI Annual Meeting
- WARREN, N.J., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced a poster presentation highlighting the positive pharmacokinetic (PK) and pharmacodynamic (PD) data from two completed clinical studies for Anaphylm will be presented at the American Academy of Allergy, Asthma, and Immunology (AAAAI) 2024 annual meeting, which will take place February 23-26 in Washington, D.C. As highlighted in the abstract, Anaphylm PK and PD data were comparable to epinephrine delivered via autoinjector or manual intramuscular injection (IM).
- 02/15/2024
|
Aquestive Therapeutics (AQST) Rises Higher Than Market: Key Facts
- The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.68, representing a +1.13% change from its previous close.
- 02/14/2024
|
Why Aquestive Therapeutics (AQST) Outpaced the Stock Market Today
- Aquestive Therapeutics (AQST) closed at $2.68 in the latest trading session, marking a +1.52% move from the prior day.
- 02/08/2024
|
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why
- Aquestive Therapeutics (AQST) reachead $2.63 at the closing of the latest trading day, reflecting a -1.5% change compared to its last close.
- 02/02/2024
|
Aquestive Therapeutics (AQST) Increases Despite Market Slip: Here's What You Need to Know
- Aquestive Therapeutics (AQST) reachead $2.39 at the closing of the latest trading day, reflecting a +0.84% change compared to its last close.
- 01/26/2024
|
Aquestive Therapeutics (AQST) Stock Slides as Market Rises: Facts to Know Before You Trade
- The latest trading day saw Aquestive Therapeutics (AQST) settling at $2.50, representing a -0.4% change from its previous close.
- 01/23/2024
|
Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
- Aquestive Therapeutics is nearing a key topline readout for its Anaphylm sublingual film, a potential groundbreaking oral epinephrine treatment for severe allergic reactions. If the data is positive, Anaphylm could be heading for a possible New Drug Application in 2024, with a potential commercial launch in 2025. Aquestive faces risks from regulatory hurdles, competition from other epinephrine treatments, and potential financial setbacks.
- 01/19/2024
|
Aquestive Therapeutics (AQST) Declines More Than Market: Some Information for Investors
- Aquestive Therapeutics (AQST) closed at $2.63 in the latest trading session, marking a -1.13% move from the prior day.
- 01/17/2024
|
Here's Why You Should Invest in Aquestive (AQST) Stock Now
- Here, we discuss some reasons why buying Aquestive Therapeutics (AQST) stock now may turn out to be a prudent move.
- 01/03/2024
|
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
- Here is how Aquestive Therapeutics (AQST) and C4 Therapeutics, Inc. (CCCC) have performed compared to their sector so far this year.
- 12/29/2023
|
What Awaits These 4 Drug Stocks That More Than Doubled in 2023?
- Here are four drug, biotech stocks, AMPH, DERM, CNTA & AQST, which have more than doubled in 2023 with room for further growth in 2024.
- 12/26/2023
|
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
- Here is how Aquestive Therapeutics (AQST) and Dynavax Technologies (DVAX) have performed compared to their sector so far this year.
- 12/13/2023
|
Best Momentum Stocks to Buy for December 1st
- LEU, AQST and TM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 1, 2023.
- 12/01/2023
|
New Strong Buy Stocks for December 1st
- AQST, TM, LEU, BWAY and MOD have been added to the Zacks Rank #1 (Strong Buy) List on December 1, 2023.
- 12/01/2023
|
New Strong Buy Stocks for November 28th
- AQST, BROS, NSSC, RIGL and RBT have been added to the Zacks Rank #1 (Strong Buy) List on November 28, 2023.
- 11/28/2023
|
Aquestive Therapeutics (AQST) Is Up 2.98% in One Week: What You Should Know
- Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 11/27/2023
|
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
- Here is how Aquestive Therapeutics (AQST) and AC Immune (ACIU) have performed compared to their sector so far this year.
- 11/27/2023
|
New Strong Buy Stocks for November 21st
- AQST, RBT, HARP, VVI and AVTX have been added to the Zacks Rank #1 (Strong Buy) List on November 21, 2023.
- 11/21/2023
|
Aquestive Therapeutics (AQST) Upgraded to Strong Buy: Here's What You Should Know
- Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 11/16/2023
|
New Strong Buy Stocks for November 16th
- IMGN, AQST, BUR, GWRE and VECO have been added to the Zacks Rank #1 (Strong Buy) List on November 16, 2023.
- 11/16/2023
|
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
- Here is how Aquestive Therapeutics (AQST) and Amneal Pharmaceuticals (AMRX) have performed compared to their sector so far this year.
- 11/10/2023
|
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic and Pharmacodynamic Studies for Anaphylm™ at American College of Allergy Asthma and Immunology (ACAAI) Annual Meeting
- WARREN, N.J., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies, today announced that two posters recapping the positive data from pharmacokinetic (PK) and pharmacodynamic (PD) pre-clinical and clinical studies of Anaphylm™ (epinephrine) Sublingual Film will be presented at the American College of Allergy Asthma and Immunology (ACAAI) annual meeting, which will be held from November 9-13 in Anaheim, California.
- 11/10/2023
|
Aquestive Therapeutics (AQST) Stock Falls Amid Market Uptick: What Investors Need to Know
- The latest trading day saw Aquestive Therapeutics (AQST) settling at $1.54, representing a -1.91% change from its previous close.
- 11/01/2023
|
Aquestive Therapeutics (AQST) Stock Sinks As Market Gains: Here's Why
- Aquestive Therapeutics (AQST) closed at $1.32 in the latest trading session, marking a -0.75% move from the prior day.
- 10/09/2023
|
ARS Pharmaceuticals Vs. Aquestive Therapeutics; Neffy CRL Creates An Opportunity For Investing In Both
- Both ARS Pharmaceuticals and Aquestive Therapeutics are developing non-injectable epinephrine products for anaphylaxis, with potential to capture significant market share from current standard (auto-injectors). At current prices I expect that upside of either stock if successful will significantly outweight downside risk for the other stock, while upside potential from both stocks is not unlikely. Risks include regulatory delays (unlikely for SPRY but possible for AQST), several competing nasal epinephrine devices under clinical development (a major risk to SPRY) and precarious financial situation of AQST.
- 09/22/2023
|
Aquestive (AQST) Up on Reaffirming Anaphylm Development Pathway
- Aquestive (AQST) stock rises 11.8% as the company intends to begin a pivotal pharmacokinetic study of Anaphylm as an oral epinephrine product candidate in the fourth quarter of 2023.
- 09/21/2023
|
Aquestive Therapeutics (AQST) Flat As Market Gains: What You Should Know
- Aquestive Therapeutics (AQST) closed at $1.66 in the latest trading session, marking no change from the prior day.
- 09/13/2023
|
Aquestive's (AQST) Libervant Accepted for FDA Review, Stock Up
- Aquestive (AQST) announces FDA acceptance of a regulatory application seeking approval for Libervant to treat pediatric patients with frequent seizure activity. The stock rises 4.7% in response.
- 09/12/2023
|
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
- WARREN, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in two upcoming investor conferences in New York, NY as follows:
- 08/23/2023
|
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.11. This compares to loss of $0.36 per share a year ago.
- 08/07/2023
|
Aquestive (AQST) to Report Q2 Earnings: What's in Store?
- Aquestive's (AQST) second-quarter 2023 revenues are likely to have been driven by rising licensed product revenues.
- 07/26/2023
|
Aquestive Therapeutics: Developing A Better Solution To A $1 Billion/Year Anaphylaxis Problem
- Anaphylm, epinephrine sublingual film is a better solution to existing and in-development epinephrine formulations to treat anaphylaxis, a $1 billion/year market. Pharmacokinetic studies have shown faster onset of action and comparable serum levels of epinephrine as existing injectable formulations. The company is finalizing the pivotal study protocol and NDA submission is expected next year, with potential approval.
- 07/25/2023
|
Aquestive Therapeutics to Report Second Quarter 2023 Financial Results and Recent Business Highlights on August 7 and Host Conference Call on August 8 at 8:00 a.m. ET
- WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that it will report results for the second quarter ended June 30, 2023, and provide an update on recent developments in its business after market close on Monday, August 7, 2023.
- 07/25/2023
|
Aquestive Therapeutics to Present Positive Topline Data from Pharmacokinetic and Pharmacodynamic Studies of Anaphylm ™ (epinephrine) Sublingual Film at Aspen Allergy Conference
- WARREN, N.J., July 25, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST) (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that two posters recapping the positive topline data from pharmacokinetic (PK) and pharmacodynamic (PD) studies of Anaphylm epinephrine sublingual film will be presented at the Aspen Allergy Conference, which will be held from July 30 – August 3 in Aspen, CO.
- 07/25/2023
|
Are Medical Stocks Lagging Aquestive Therapeutics (AQST) This Year?
- Here is how Aquestive Therapeutics (AQST) and HCA Healthcare (HCA) have performed compared to their sector so far this year.
- 07/14/2023
|
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
- Here is how Aquestive Therapeutics (AQST) and Corvus Pharmaceuticals (CRVS) have performed compared to their sector so far this year.
- 05/26/2023
|
Are You Looking for a Top Momentum Pick? Why Aquestive Therapeutics (AQST) is a Great Choice
- Does Aquestive Therapeutics (AQST) have what it takes to be a top stock pick for momentum investors? Let's find out.
- 05/11/2023
|
Best Momentum Stocks to Buy for May 9th
- AQST, PLTK and WWD made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on May 9, 2023.
- 05/09/2023
|
Aquestive Therapeutics (AQST) Tops Q1 Earnings and Revenue Estimates
- Aquestive Therapeutics (AQST) came out with quarterly earnings of $0.11 per share, beating the Zacks Consensus Estimate of a loss of $0.10 per share. This compares to loss of $0.32 per share a year ago.
- 05/02/2023
|
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
- WARREN, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in two upcoming investor conferences as follows:
- 04/26/2023
|
Aquestive Therapeutics, Inc. (AQST) Q4 2022 Earnings Call Transcript
- Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q4 2022 Results Conference Call March 8, 2023 8:00 AM ET Company Participants Bennett Watson - Westwicke, Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer Steve Wargacki - Head of R&D Ken Truitt - Chief Medical Officer Ken Marshall - Chief Commercial Officer Conference Call Participants Francois Brisebois - Oppenheimer Thomas Flaten - Lake Street Capital Markets Ram Selvaraju - HC Wainwright James Malloy - Alliance Global Partners Operator Good morning, and welcome to the Aquestive Therapeutics Fourth Quarter and Full Year 2022 Conference Call. At this time, all participants are in a listen only-mode.
- 03/08/2023
|
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -9.52% and 7.57%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
- 03/07/2023
|
Aquestive Therapeutics to Report Fourth Quarter 2022 Financial Results and Recent Business Highlights on March 7 and Host Conference Call on March 8 at 8:00 a.m. ET
- WARREN, N.J., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), (the “Company” or “Aquestive”), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, today announced that it will report results for fourth quarter ended December 31, 2022, and provide an update on recent developments in its business after market close on Tuesday, March 7, 2023.
- 02/22/2023
|
Aquestive Therapeutics: Going All-In On AQST-109
- Aquestive Therapeutics has been making deals to generate cash to help develop their epinephrine candidate, AQST-109. Aquestive appears to be going all-in on AQST-109's clinical and commercial success. I intend to provide a brief background on AQST-109 and will review the company's efforts to prioritize its development.
- 11/29/2022
|
Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences
- WARREN, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying complex delivery methods, announced today that the management team will participate in the two upcoming investor conferences as follows:
- 11/15/2022
|
Aquestive Therapeutics to Present Positive Data from Pharmacokinetic Studies for AQST-109 (epinephrine sublingual film) at American Academy of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting
- WARREN, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying complex delivery methods, will present three abstracts recapping positive data from its completed pharmacokinetic studies of AQST-109 (epinephrine sublingual film) at the American College of Allergy Asthma and Immunology (ACAAI) Annual Scientific Meeting, which will be held from November 10-14, in Louisville, Kentucky.
- 11/09/2022
|
My Top 5 U.S. Stocks Under $10
- After a rough September, we're approaching the season historically known for stronger performance. Although small-cap stocks can be more volatile than large-caps, cheap stocks often have high return potential. Offering attractive valuations, above-average growth, and strong balance sheets, our Quant-based picks under $10 have vastly outperformed both Large and Small-cap indexes.
- 11/03/2022
|
Aquestive Therapeutics, Inc. (AQST) Q3 2022 Earnings Call Transcript
- Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q3 2022 Earnings Conference Call November 2, 2022 8:00 AM ET Company Participants Bennett Watson - Westwicke, Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Senior Vice President, Chief Financial Officer Ken Truitt - Chief Medical Officer Ken Marshall - Chief Commercial Officer Steve Wargacki - Head of R&D Conference Call Participants Dennis Resnick - BMO Jason Butler - JMP Securities Francois Brisebois - Oppenheimer Thomas Flaten - Lake Street Capital Markets Andreas Argyrides - Wedbush Laura Searle - Alliance Operator Good morning, and welcome to the Aquestive Therapeutics Third Quarter 2022 Conference Call. At this time, all participants are in a listen only-mode.
- 11/02/2022
|
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 23.33% and 7.30%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
- 11/01/2022
|
Aquestive Therapeutics to Report Third Quarter 2022 Financial Results and Recent Business Highlights on November 1 and Host Conference Call on November 2 at 8:00 a.m. ET
- WARREN, N.J., Oct. 19, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing current standards of care to solve patients' problems through simplifying complex delivery methods, today announced that it will report results for third quarter ended September 30, 2022, and provide an update on recent developments in its business after market close on Tuesday, November 1, 2022.
- 10/19/2022
|
Aquestive Therapeutics (AQST) Stock Gains on Positive Data for EpiPen Rival
- Source: Rob Byron / Shutterstock.com Aquestive Therapeutics (NASDAQ: AQST ) stock is taking off on Tuesday as investors react to positive clinical trial data from the pharmaceutical company. Aquestive Therapeutics is developing a rival to EpiPen and the results from its Phase 2 clinical trial are in.
- 09/27/2022
|
Aquestive Therapeutics: Waiting To Buy After FDA Goes Halfway With Libervant
- After 8 months of waiting for an update from the FDA, the agency finally announced a tentative approval for Aquestive's Libervant. Unfortunately, the company cannot market the product. Aquestive Therapeutics recently reported their Q2 earnings, which revealed a beat on revenue with the EPS in-line with expectations. Aquestive has upped their full-year guidance for both revenue and EPS.
- 09/02/2022
|
Aquestive Therapeutics to Participate in Two Investor Conferences in September
- WARREN, N.J., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (Nasdaq: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the two upcoming investor conferences in September as follows:
- 08/31/2022
|
How Inflation Impacts Penny Stocks and the Stock Market
- Use these tips for trading penny stocks with high inflation The post How Inflation Impacts Penny Stocks and the Stock Market appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 08/13/2022
|
Aquestive Therapeutics, Inc. (AQST) CEO Dan Barber on Q2 2022 Results - Earnings Call Transcript
- Aquestive Therapeutics, Inc. (NASDAQ:AQST ) Q2 2022 Earnings Conference Call August 3, 2022 8:00 AM ET Company Participants Bennett Watson - ICR Westwicke, Investor Relations Dan Barber - Chief Executive Officer Ernie Toth - Chief Financial Officer Dr. Steve Wargacki - VP of R&D Ken Marshall - Chief Commercial Officer. Conference Call Participants Evan Hua - BMO Securities Jason Butler - JMP Securities Thomas Flaten - Lake Street Capital Andreas Argyrides - Wedbush Ram Selvaraju - H.C.
- 08/03/2022
|
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 12.20% and 32.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
- 08/02/2022
|
Aquestive Therapeutics: Sell-Off Prompts A Change In Tactics
- Over the past couple of years, my Aquestive Therapeutics (AQST) thesis has been fixated on valuation and their two most important value drivers, Libervant and AQST-109. AQST-109 is the first and only oral epinephrine candidate to establish grades comparable to epinephrine auto-injectors. Aquestive expects to start the pivotal study before year-end.
- 05/26/2022
|
Aquestive Therapeutics to Participate in H.C. Wainwright Global Investment Conference
- WARREN, N.J., May 10, 2022 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company advancing medicines to solve patients' problems with current standards of care and provide transformative products to improve their lives, announced today that the management team will participate in the H.C. Wainwright Global Investment Conference from May 23rd to May 26th.
- 05/10/2022
|
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 28.89% and 25.18%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- 05/03/2022
|
Aquestive's AQST-109 Receives Fast Track Tag For Allergic Reactions
- The FDA has granted Fast Track Designation to Aquestive Therapeutics Inc's (NASDAQ: AQST) AQST-109 for allergic reactions. AQST-109 is an orally delivered epinephrine-based product candidate for the emergency treatment of allergic reactions, including anaphylaxis.
- 03/17/2022
|
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2021 Results - Earnings Call Transcript
- Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2021 Results - Earnings Call Transcript
- 03/09/2022
|
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -2.70% and 12.98%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
- 03/08/2022
|
Aquestive Therapeutics: Discounted With An Incredible Risk-Reward For 2022
- Aquestive Therapeutics made several advancements last year that have set the stage for a potentially transformative year in 2022. Unfortunately, the share price ended the year on a sour note.
- 02/22/2022
|
Why Aquestive Therapeutics Dived by 29% Today
- A decision on a crucial regulatory filing is being delayed indefinitely.
- 12/21/2021
|
Aquestive Therapeutics Stock (AQST): Why The Price Substantially Fell Today
- The stock price of Aquestive Therapeutics, Inc. (NASDAQ: AQST) fell by over 30% pre-market today. This is why it happened.
- 12/21/2021
|
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options
- Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.
- 12/20/2021
|
Aquestive Therapeutics: Looking To End 2021 On A Bullish Note
- Aquestive Therapeutics is moving closer to Libervant's PDUFA date in December. If approved, Aquestive will finish 2021 on a bullish note that can be sustained into 2022. Aquestive has fought through COVID-19 headwinds and was able to report a strong beat on Q3 with SYMPAZAN continuing to show strong growth over the past 11 consecutive quarters.
- 11/29/2021
|
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2021 Results - Earnings Call Transcript
- Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2021 Results - Earnings Call Transcript
- 11/03/2021
|
Aquestive Therapeutics (AQST) Reports Q3 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 7.50% and 10.45%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
- 11/02/2021
|
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 10/26/2021
|
Aquestive Therapeutics to Report Third Quarter 2021 Financial Results and Recent Business Highlights on November 2 and Host Conference Call on November 3 at 8:00 a.m. ET
- WARREN, N.J., Oct. 14, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it will report results for third quarter ended September 30, 2021 and provide an update on recent developments in its business after market close on Tuesday, November 2, 2021.
- 10/14/2021
|
Aquestive Therapeutics Reaches Agreement to Extend Principal Payments Due Under Credit Facility to March 30, 2023 and Receives Bridge Waiver of Principal Debt Payment in Advance of Concluding Formal Agreement
- WARREN, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it has reached an agreement with its lenders providing for a bridge waiver of the first principal payment due under its 12.5% Senior Secured Notes (the “Notes”) in order to provide sufficient time for the parties to execute a definitive agreement to extend the time when the first principal payment is due under the Notes to March 30, 2023.
- 10/06/2021
|
Aquestive Therapeutics to Participate in 12th Annual Wedbush PacGrow Healthcare Virtual Conference
- WARREN, N.J., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that the management team will participate in a panel entitled “Got My Mind Set On You - Advancing Novel Epilepsy Targets” at the 12th Annual Wedbush PacGrow Healthcare Virtual Conference to be held on Wednesday, August 11, 2021 at 11:30 am ET. The team will also host one-on-one investor meetings throughout the conference.
- 08/06/2021
|
Aquestive Therapeutics' (AQST) CEO Keith Kendall on Q2 2021 Results - Earnings Call Transcript
- Aquestive Therapeutics' (AQST) CEO Keith Kendall on Q2 2021 Results - Earnings Call Transcript
- 08/04/2021
|
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 21.43% and 44.42%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
- 08/03/2021
|
Aquestive Therapeutics Reports Second Quarter 2021 Financial Results, Provides Business Update and Raises Full Year Revenue Guidance
- WARREN, N.J., Aug. 03, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today reported financial results for the second quarter ended June 30, 2021 and provided an update on recent developments in its business.
- 08/03/2021
|
Earnings Preview: Aquestive Therapeutics (AQST) Q2 Earnings Expected to Decline
- Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/27/2021
|
4 Stocks To Watch With The Stock Market Down Today
- Which Penny Stocks Are Investors Watching After the Stock Market Crash? The post 4 Stocks To Watch With The Stock Market Down Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
- 07/19/2021
|
Aquestive Therapeutics Announces FDA Acceptance of New Drug Application (NDA) Resubmission for Libervant™ (diazepam) Buccal Film
- WARREN, N.J., July 19, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing the resubmission of the New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters. The FDA has assigned a Prescription Drug User Fee Act (“PDUFA”) target goal date of December 23, 2021.
- 07/19/2021
|
Aquestive Therapeutics Resubmits New Drug Application for Libervant™ (diazepam) Buccal Film
- WARREN, N.J., June 24, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters in response to the September 25, 2020 Complete Response Letter (CRL) from the FDA. The submission included additional statistical modeling and supporting analyses of the existing clinical data based upon the guidance received from the Agency.
- 06/24/2021
|
Aquestive Therapeutics: Bullish Outlook Continues To Harden
- Aquestive Therapeutics is moving closer to resubmitting Libervant's NDA. The company expects to submit the NDA by the end of this month, which could put the PDUFA date in 2021. Aquestive continues to fight through COVID-19 headwinds and was able to report impressive Q1 numbers with SYMPAZAN recording strong year-over-year growth.
- 06/23/2021
|
Aquestive Therapeutics Announces Leadership Transition of Chief Financial Officer
- WARREN, N.J., June 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today announced that A. Ernest (Ernie) Toth, Jr., a seasoned financial executive and currently serving the Company as the interim Chief Financial Officer, has transitioned to the permanent role of Senior Vice President and Chief Financial Officer effective immediately.
- 06/21/2021
|
Aquestive Therapeutics to Participate in JMP Securities and BMO Capital Market Investor Conferences
- WARREN, N.J., June 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that the management team will participate in two upcoming investor conferences in June.
- 06/09/2021
|
Aquestive Therapeutics to Participate in 2021 RBC Capital Markets Global Healthcare Conference
- WARREN, N.J., May 11, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the 2021 RBC Capital Markets Global Healthcare Conference to be held virtually May 19, 2021 at 9:45 ET. Aquestive will also host one-on-one investor meetings throughout the conference.
- 05/11/2021
|
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2021 Results - Earnings Call Transcript
- Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2021 Results - Earnings Call Transcript
- 05/05/2021
|
Aquestive Therapeutics (AQST) Reports Q1 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 6.82% and 21.55%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
- 05/04/2021
|
Aquestive Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
- WARREN, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today reported financial results for the first quarter ended March 31, 2021 and provided an update on recent developments in its business.
- 05/04/2021
|
DEADLINE TODAY: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 30, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 2, 2019 and September 25, 2020, inclusive...
- 04/30/2021
|
AQST Final Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds Aquestive Therapeutics, Inc. Investors of Class Action and Lead Plaintiff Deadline: April 30, 2021
- NEW YORK--(BUSINESS WIRE)--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aquestive securities between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's si
- 04/30/2021
|
AQST IMPORTANT DEADLINE FRIDAY: ROSEN, A LEADING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important April 30 Deadline in Securities Class Action - AQST
- NEW YORK, April 29, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/29/2021
|
DEADLINE TOMORROW: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 29, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 2, 2019 and September 25, 2020, inclusive...
- 04/29/2021
|
APRIL 30, 2021 AQST INVESTOR DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.
- New York, New York--(Newsfile Corp. - April 29, 2021) - Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) from December 2, 2019, through September 25, 2020 (the "Class Period"). The lawsuit filed in...
- 04/29/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- New York, New York--(Newsfile Corp. - April 28, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 04/28/2021
|
FRIDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- Los Angeles, California--(Newsfile Corp. - April 27, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between December 2, 2019 and September 25, 2020, inclusive...
- 04/27/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- NEW YORK, April 26, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S.
- 04/26/2021
|
Rosen, Top Ranked Global Investor Counsel, Encourages Aquestive Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important Deadline in Securities Class Action - AQST
- New York, New York--(Newsfile Corp. - April 25, 2021) - WHY: New York, N.Y., April 25, 2021. Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline.SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without...
- 04/25/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- New York, New York--(Newsfile Corp. - April 22, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 04/22/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- New York, New York--(Newsfile Corp. - April 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 04/21/2021
|
Aquestive Therapeutics to Report First Quarter 2021 Financial Results and Recent Business Highlights on May 4 and Host Conference Call on May 5 at 8:00 a.m. ET
- WARREN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it will report results for first quarter ended March 31, 2021 and provide an update on recent developments in its business after market close on Tuesday, May 4, 2021.
- 04/21/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- NEW YORK, April 19, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S.
- 04/19/2021
|
AQST INVESTOR NOTICE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - AQST
- NEW YORK, April 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/17/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- NEW YORK, April 13, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S.
- 04/13/2021
|
Rosen, Leading Trial Attorneys, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AQST
- New York, New York--(Newsfile Corp. - April 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline.SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...
- 04/12/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- New York, New York--(Newsfile Corp. - April 10, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 04/10/2021
|
UPCOMING DEADLINE REMINDER: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, April 9, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 2, 2019 and September 25, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before April 30, 2021.
- 04/09/2021
|
AQST INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.
- NEW YORK, April 7, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) from December 2, 2019, through September 25, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the District of New Jersey alleges violations of the Securities Exchange Act of 1934.
- 04/07/2021
|
Aquestive Therapeutics: Remaining Bullish On PharmFilm Technology Opportunities
- Aquestive Therapeutics is a world leader in oral film drug delivery with its PharmFilm technology. The company has developed several approved products that offer several advantage over other delivery methods.
- 04/07/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- NEW YORK, April 6, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S.
- 04/06/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- NEW YORK, April 4, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S.
- 04/04/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- New York, New York--(Newsfile Corp. - April 4, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 04/04/2021
|
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - AQST
- NEW YORK, April 1, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 04/01/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- NEW YORK, March 31, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S.
- 03/31/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- New York, New York--(Newsfile Corp. - March 29, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about...
- 03/29/2021
|
AQST LOSS ALERT: ROSEN, A LONGSTANDING LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - AQST
- New York, New York--(Newsfile Corp. - March 29, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline.SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 03/29/2021
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AQST
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April 30, 2021 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen
- 03/26/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Reminds Investors of Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, March 25, 2021 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between December 2, 2019 and September 25, 2020, inclusive (the ''Class Period''), are encouraged to contact the firm before April 30, 2021.
- 03/25/2021
|
Aquestive Therapeutics Successfully Demonstrates Repeatable and Predictable Oral Sublingual Film Administration of Epinephrine
- WARREN, N.J., March 25, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, will provide later this morning an in-depth overview of its systemic epinephrine drug delivery program combining its novel prodrug technology and its PharmFilm® technology. At the R&D event, the management team and KOLs will share an extensive review of the science, clinical results, and development strategy associated with two prodrug candidates in development for the treatment of allergic reactions including anaphylaxis. Aquestive has submitted multiple U.S. and foreign patent applications that cover the technology and formulations for its two prodrug candidates, AQST-108 and AQST-109. If granted, Aquestive anticipates patent protection for both drug candidates through at least 2037.
- 03/25/2021
|
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors
- LOS ANGELES, March 24, 2021 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that a class action lawsuit has been filed on behalf of persons and entities that purchased or otherwise acquired Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020 , inclusive (the "Class Period").
- 03/24/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- NEW YORK, March 24, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S.
- 03/24/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
- BENSALEM, Pa., March 22, 2021 /PRNewswire/ -- Law Offices of Howard G.
- 03/22/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- New York, New York--(Newsfile Corp. - March 21, 2021) - Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S. Willoughby at newaction@pomlaw.com or 888-476-6529, ext. 7980.The investigation concerns whether Aquestive and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining...
- 03/21/2021
|
Rosen, Global Investor Counsel, Encourages Aquestive Therapeutics, Inc. Investors with Large Losses to Secure Counsel Before Important Deadline - AQST
- New York, New York--(Newsfile Corp. - March 20, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline.SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees...
- 03/20/2021
|
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQST
- NEW YORK, March 18, 2021 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST). Such investors are advised to contact Robert S.
- 03/18/2021
|
AQST INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.
- NEW YORK, March 18, 2021 /PRNewswire/ -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) from December 2, 2019, through September 25, 2020 (the "Class Period"). The lawsuit filed in the United States District Court for the District of New Jersey alleges violations of the Securities Exchange Act of 1934.
- 03/18/2021
|
ROSEN, NATIONAL TRIAL COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - AQST
- NEW YORK, March 17, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
- 03/17/2021
|
AQST INVESTOR LAWSUIT DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion In a Securities Class Action Against Aquestive Therapeutics, Inc.
- NEW YORK, March 17, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the securities of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) from December 2, 2019, through September 25, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the District of New Jersey alleges violations of the Securities Exchange Act of 1934.
- 03/17/2021
|
AQST DEADLINE: Zhang Investor Law Alerts Investors of Deadline in Securities Class Action Lawsuit Against Aquestive Therapeutics, Inc. – AQST
- NEW YORK, March 16, 2021 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”).
- 03/16/2021
|
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
- LOS ANGELES, March 16, 2021 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020 , inclusive (the "Class Period"). If you suffered a loss on your Aquestive investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/aquestive-therapeutics-inc/.
- 03/16/2021
|
AQST Investor Notice: Rosen, A Leading Investor Rights Law Firm, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline - AQST
- New York, New York--(Newsfile Corp. - March 12, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"), of the important April 30, 2021 lead plaintiff deadline.SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket...
- 03/12/2021
|
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Aquestive Therapeutics, Inc. (AQST)
- BENSALEM, Pa.--(BUSINESS WIRE)---- $AQST #CLASSACTION--Law Offices of Howard G. Smith reminds investors of the upcoming April 30, 2021 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). Investors suffering losses on their Aquestive investments are encouraged to contact the Law Offices of Howard G. Smith to di
- 03/10/2021
|
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2020 Results - Earnings Call Transcript
- Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q4 2020 Results - Earnings Call Transcript
- 03/10/2021
|
ROSEN, A TOP RANKED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – AQST
- NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April 30, 2021 lead plaintiff deadline.
- 03/10/2021
|
Aquestive Therapeutics (AQST) Reports Q4 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of -30.43% and 11.56%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
- 03/09/2021
|
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
- WARREN, N.J., March 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today reported financial results for the fourth quarter and full year ended December 31, 2020 and provided an update on recent developments in its business.
- 03/09/2021
|
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Aquestive Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline – AQST
- NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”), of the important April 30, 2021 lead plaintiff deadline. SO WHAT: If you purchased Aquestive securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangemen
- 03/08/2021
|
Aquestive Therapeutics Earnings Preview
- Aquestive Therapeutics (NASDAQ:AQST) announces its next round of earnings this Tuesday, March 09. Here is Benzinga's everything-that-matters guide for this Tuesday's Q4 earnings announcement.
- 03/08/2021
|
ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline – AQST
- NEW YORK, March 06, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 30, 2021.
- 03/06/2021
|
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES, March 5, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) for violations of §§10(b) and 20(a) of the...
- 03/05/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Aquestive Therapeutics, Inc. (AQST) Investors
- BENSALEM, Pa.--(BUSINESS WIRE)---- $AQST #CLASSACTION--Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) securities between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). Aquestive investors have until April 30, 2021 to file a lead plaintiff motion. Investors suffering losses on their Aquestive investments are encouraged to contact the Law Offices
- 03/05/2021
|
AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
- NEW YORK, March 05, 2021 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) and certain of its officers, on behalf of shareholders who purchased or otherwise acquired Aquestive securities between December 2, 2019 and September 25, 2020, inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: www.bgandg.com/aqst.
- 03/05/2021
|
Aquestive Therapeutics to Host Investor & Analyst Virtual Epinephrine Drug Delivery R&D Event on March 25 at 9:00 a.m. ET
- WARREN, N.J., March 05, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it will host a virtual investor and analyst epinephrine drug delivery research and development event on Thursday, March 25, 2021 at 9:00 am ET.
- 03/05/2021
|
SHAREHOLDER ALERT: Robbins LLP Announces That Aquestive Therapeutics, Inc. (AQST) is Being Sued for Misleading Shareholders
- SAN DIEGO & WARREN, N.J.--(BUSINESS WIRE)---- $AQST #ClassAction--Shareholder rights law firm Robbins LLP announces that a purchaser of Aquestive Therapeutics, Inc. (NASDAQ: AQST) filed a class action complaint against the Company and its officers and directors for alleged violations of the Securities Exchange Act of 1934 between December 2, 2019 and September 25, 2020. Aquestive is a specialty pharmaceutical company that develops products to address unmet medical needs. The Company's most advanced proprietary produc
- 03/04/2021
|
The Law Offices of Frank R. Cruz Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $AQST #investors--The Law Offices of Frank R. Cruz Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
- 03/04/2021
|
AQUESTIVE THERAPEUTICS, INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP notifies investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey
- LEAD PLAINTIFF DEADLINE IS APRIL 30, 2021 LEAD PLAINTIFF DEADLINE IS APRIL 30, 2021
- 03/04/2021
|
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $AQST #AQST--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc.
- 03/04/2021
|
ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages Aquestive Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline - AQST
- NEW YORK, March 3, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020,...
- 03/03/2021
|
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
- LOS ANGELES--(BUSINESS WIRE)---- $AQST #CLASSACTION--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your Aquestive investments or would like to inquire about potentially pursuing claims to recover your loss under the federal
- 03/03/2021
|
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aquestive Therapeutics, Inc. (AQST) on Behalf of Investors
- BENSALEM, Pa--(BUSINESS WIRE)---- $AQST #CLASSACTION--Law Offices of Howard G. Smith announces an investigation on behalf of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) investors concerning the Company's possible violations of federal securities laws. Aquestive is a specialty pharmaceutical company. Its most advanced proprietary product candidate is Libervant, a buccal soluble film formulation of diazepam for the treatment of recurrent epileptic seizures. On December 2, 2019, Aquestive
- 03/03/2021
|
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
- LOS ANGELES--(BUSINESS WIRE)---- $AQST #AQST--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Aquestive Therapeutics, Inc.
- 03/03/2021
|
Why Ovid, KemPharm, Sorrento, Aquestive Are Rallying
- Ovid Therapeutics Inc. (NASDAQ: OVID), KemPharm Inc (NASDAQ: KMPH), Aquestive Therapeutics Inc (NASDAQ: AQST) and Sorrento Therapeutics, Inc. (NASDAQ: SRNE) were among the health care gainers in Wednesday's premarket session. Here's what investors need to know.
- 03/03/2021
|
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc. (AQST)
- NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. (“Aquestive”) (NASDAQ: AQST) in the United States District Court for the District of New Jersey on behalf of those who purchased or acquired the securities of Aquestive between December 2, 2019, through September 25, 2020, inclusive (the “Class Period”). The lawsuit seeks to recover damages for investors under the federal securities laws.
- 03/03/2021
|
AQST Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Aquestive Therapeutics, Inc. Investors of Class Action and Encourages Shareholders to Contact the Firm
- NEW YORK, March 3, 2021 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or "the Company") (NASDAQ: AQST) and certain of its officers, on behalf of...
- 03/03/2021
|
AQST Stock Price Increases Over 20% Pre-Market: Why It Happened
- The stock price of Aquestive Therapeutics, Inc. (Nasdaq: AQST) is trading at over 20% pre-market. This is why it happened.
- 03/03/2021
|
AQST INVESTOR ALERT: Bernstein Liebhard LLP Announces that a Securities Class Action Lawsuit Has Been Filed Against Aquestive Therapeutics, Inc.
- NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Bernstein Liebhard, a nationally acclaimed investor rights law firm, announces that a securities class action lawsuit has been filed on behalf of investors who purchased or acquired the securities of Aquestive Therapeutics, Inc. (“Aquestive” or the “Company”) (NASDAQ: AQST) from December 2, 2019, through September 25, 2020 (the “Class Period”). The lawsuit filed in the United States District Court for the District of New Jersey alleges violations of the Securities Exchange Act of 1934.
- 03/02/2021
|
Pomerantz Law Firm Announces the Filing of a Class Action against Aquestive Therapeutics, Inc. and Certain Officers - AQST
- NEW YORK, March 1, 2021 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aquestive Therapeutics, Inc. ("Aquestive" or the "Company") (NASDAQ: AQST) and certain of its officers. The class action, filed in United States District Court for the...
- 03/01/2021
|
Aquestive Therapeutics to Announce Fourth Quarter and Year End 2020 Financial Results and Recent Business Highlights on March 9 and Host Conference Call on March 10 at 8:00 a.m. ET
- WARREN, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it will report results for the fourth quarter and year ended December 31, 2020 and provide a business update after market close on Tuesday, March 9, 2021.
- 02/17/2021
|
Aquestive Therapeutics Strengthens Board of Directors with Appointments of Julie Krop, M.D., and Marco Taglietti, M.D.
- WARREN, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today announced the appointment of Julie Krop, M.D., Chief Medical Officer of Freeline Therapeutics (NASDAQ: FRLN), and Marco Taglietti, M.D., Director, President and Chief Executive Officer of SCYNEXIS (NASDAQ: SCYX), to the Board of Directors of the Company effective February 10, 2021. Aquestive also announced the resignation of Douglas K. Bratton from the Board of Directors after more than 17 years of service. Aquestive's Board of Directors will now be comprised of eight Directors, seven of whom are independent. Dr. Krop will serve as a member of the Board's Nominating and Corporate Governance Committee and Dr. Taglietti will serve as a member of the Board's Audit Committee.
- 02/09/2021
|
Aquestive Therapeutics Appoints Mark Lepore, MD, as Chief Medical Officer for Allergy
- WARREN, N.J., Jan. 28, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today announced the appointment of Mark Lepore, MD, as the Chief Medical Officer for Allergy.
- 01/28/2021
|
Aquestive Therapeutics to Present at Two Upcoming Investor Conferences
- WARREN, N.J., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that the management team will participate in fireside chats at the H.C. Wainwright BioConnect 2021 Conference to be held virtually January 11-14, and at the Westwicke Healthcare Day to be held virtually on January 14 during the ICR Conference 2021. Aquestive will host one-on-one investor meetings during the week of January 11 in conjunction with the ICR Conference. Presentation times and availabilities are as follows:
- 01/04/2021
|
Aquestive Therapeutics: Back From The Brink, ~57% Upside Potential In New Asset Structuring
- Aquestive Therapeutics are back from the brink, with key advancements in Libervant resubmission and longevity in shareholder value creation. The company entered into a royalty agreement for KYNMOBI, which will drive long-tailed asset returns for the creation of value for shareholders.
- 12/16/2020
|
Aquestive Therapeutics to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
- WARREN, N.J., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that the management team will participate in a fireside chat at the Piper Sandler Virtual 32nd Annual Healthcare Conference to be held December 1-3, 2020. Aquestive will host one-on-one investor meetings on December 2, 2020.
- 11/25/2020
|
Aquestive Therapeutics Receives First Milestone Payment from KYNMOBI™ Monetization
- Receives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 million Receives first milestone payment of $10 million, bringing total fourth quarter proceeds to $50 million
- 11/23/2020
|
Aquestive Therapeutics Completes FDA Type A Meeting on Libervant
- WARREN, N.J., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today the completion of a Type A meeting with the U.S. Food and Drug Administration (FDA) confirming a pathway for resubmission for approval of the Company's drug candidate Libervant™ (diazepam) Buccal Film for management of seizure clusters.
- 11/18/2020
|
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2020 Results - Earnings Call Transcript
- Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q3 2020 Results - Earnings Call Transcript
- 11/08/2020
|
Aquestive Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Update
- WARREN, N.J., Nov. 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, today reported financial results for the third quarter ended September 30, 2020 and provided an update on recent developments in its business.
- 11/04/2020
|
Aquestive Therapeutics Signs Royalty Monetization Agreement with Marathon Asset Management for up to $125 Million
- WARREN, N.J., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients' unmet needs and solve therapeutic problems, announced today that it has entered a royalty monetization agreement with an affiliate of Marathon Asset Management, a leading global investment firm (“Marathon”), that will result in proceeds to the Company of up to $125 million. In exchange for this funding, Marathon will be entitled to receive all royalties and other payments due under Aquestive's license agreement with Sunovion Pharmaceuticals Inc. (“Sunovion”) as a result of Sunovion's commercialization of KYNMOBI™ (apomorphine HCI) sublingual film for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease. Net proceeds of the transaction will be used to repay certain senior notes and fund the Company's ongoing development and commercialization of its proprietary product pipeline candidates, as well as for working capital purposes. KYNMOBI received approval from the U.S. Food and Drug Administration (FDA) on May 21, 2020.
- 11/03/2020
|
Aquestive Therapeutics (AQST) in Focus: Stock Moves 6.4% Higher
- Aquestive Therapeutics (AQST) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
- 08/18/2020
|
Aquestive Therapeutics (AQST) Investor Presentation - Slideshow
- The following slide deck was published by Aquestive Therapeutics, Inc. in conjunction with this event..
- 08/13/2020
|
Aquestive Therapeutics Receives FDA Fast Track Designation for AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Treatment of Allergic Reactions Including Anaphylaxis
- * Finalizing preparations for pharmacokinetic (PK) clinical trials of AQST-108 * First planned PK clinical trial expected to begin during the third quarter of 2020WARREN, N.J., Aug. 10, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of allergic reactions (Type 1), including anaphylaxis, using Aquestive’s proprietary PharmFilm® technologies. Fast Track is an FDA process designed to facilitate the development and expedite the review of therapies to treat serious conditions and fill unmet medical needs. Programs with Fast Track designation may benefit from early and frequent communication with the FDA, eligibility for FDA accelerated approval and priority review, if relevant criteria are met, in addition to a rolling submission of the marketing application.Aquestive received confirmation from the FDA in July 2020 that the agency completed its safety review of its IND and concluded that the Company could proceed with the first planned PK clinical trials of AQST-108. As such, the Company expects to commence its first PK clinical trial utilizing a four-treatment crossover design to compare the pharmacokinetics and pharmacodynamics of AQST-108 to that of epinephrine administered as subcutaneous and intramuscular injections before the end of the third quarter of 2020. “Fast Track designation confirms the unmet medical need for patients who are at risk for allergic reactions including anaphylaxis but reluctant and hesitant to use the standard of care, subcutaneous and intramuscular injections. We believe that AQST-108, a highly portable, easy-to-administer sublingual film formulation delivering systemic epinephrine, satisfies this unmet medical need for this large underserved patient population,” said Keith J. Kendall, Chief Executive Officer of Aquestive. “Our first planned PK clinical trial will begin this quarter.”About AQST-108 AQST-108 is a “first of its kind” oral sublingual film formulation delivering systemic epinephrine for the treatment of allergic reactions (Type 1), including anaphylaxis, using Aquestive’s proprietary PharmFilm® technologies. Anaphylaxis is a potentially life-threatening systemic allergic reaction, with an estimated incidence of 50 to 112 episodes per 100,000 people per year. The frequency of hospital admissions for anaphylaxis has increased 500-700% in the last 10-15 years.1 The most common causes of reactions that can include anaphylaxis are medications, foods (such as peanuts), and venom from insect stings. Epinephrine injection is the current standard of treatment intended to reverse the potentially severe manifestation of anaphylaxis, which may include red rash, throat swelling, respiratory problems, gastrointestinal distress and loss of consciousness.About Aquestive Therapeutics Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.Forward-Looking StatementThis press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding therapeutic benefits and plans and objectives for regulatory approvals of AQST-108, LibervantTM and our other product candidates; ability to obtain FDA approval and advance AQST-108, Libervant and our other product candidates to the market, statements about our growth and future financial and operating results and financial position, regulatory approval and pathways, clinical trial timing and plans, our and our competitors’ orphan drug approval and resulting drug exclusivity for our products or products of our competitors, short-term and long-term liquidity and cash requirements, cash funding and cash burn, business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are also subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials; on regulatory submissions and regulatory reviews and approvals of our product candidates; pharmaceutical ingredient and other raw materials supply chain, manufacture, and distribution; sale of and demand for our products; our liquidity and availability of capital resources; customer demand for our products and services; customers’ ability to pay for goods and services; and ongoing availability of an appropriate labor force and skilled professionals. Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic.These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans; risk of delays in FDA approval of Libervant and our other drug candidates or failure to receive approval; risk of our ability to demonstrate to the FDA “clinical superiority” within the meaning of the FDA regulations of our drug candidate Libervant relative to FDA-approved diazepam rectal gel and nasal spray products including by establishing a major contribution to patient care within the meaning of FDA regulations relative to the approved products as well as risks related to other potential pathways or positions which are or may in the future be advanced to the FDA to overcome the seven year orphan drug exclusivity granted by the FDA for the approved nasal spray product of a competitor in the U.S. and there can be no assurance that we will be successful; risk that a competitor obtains FDA orphan drug exclusivity for a product with the same active moiety as any of our other drug products for which we are seeking FDA approval and that such earlier approved competitor orphan drug blocks such other product candidates in the U.S. for seven years for the same indication; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risks and uncertainties concerning any potential monetization of royalty and other revenue stream of KYNMOBI (apomorphine) and of sufficiency of net proceeds of any such monetization after satisfaction of and compliance with 12.
- 08/10/2020
|
Aquestive Therapeutics (AQST) Gets a Buy Rating from Wedbush - Markets
- In a report issued on August 7, Liana Moussatos from Wedbush maintained a Buy rating on Aquestive Therapeutics (AQST –
- 08/09/2020
|
Aquestive Therapeutics, Inc. (AQST) Q2 2020 Earnings Call Transcript
- Good morning and welcome to today's call to review Aquestive Therapeutics' results for the second-quarter 2020 and business highlights. On today's call, I am joined by Keith Kendall, president and chief executive officer; and John Maxwell, chief financial officer, who are going to provide an overview of recent business developments and performance in the second quarter.
- 08/05/2020
|
Aquestive Therapeutics (AQST) Reports Q2 Loss, Tops Revenue Estimates
- Aquestive Therapeutics (AQST) delivered earnings and revenue surprises of 83.72% and 137.27%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
- 08/04/2020
|
Aquestive Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Update: AQST-108 Progress Remains On Track; Libervant PDUFA Goal Date Approaches
- * Generated 59% year-over-year revenue growth for Sympazan®(clobazam) * FDA completed safety review of IND for AQST-108 (epinephrine) and approved commencement of first planned pharmacokinetics (PK) clinical trials * Continues to advance Libervant™ (diazepam) through FDA review and on-going inspection process of manufacturing and clinical investigational sites * Ongoing process for potential monetization of royalty rights in KYNMOBI™ (apomorphine) continues * Re-affirms full year 2020 financial guidance * Hosts conference call at 8:00 a.m. ET on August 5, 2020WARREN, N.J., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today reported financial results for the second quarter ended June 30, 2020 and provided an update on recent developments in its business. Keith J. Kendall, President and Chief Executive Officer of Aquestive, stated, “While continuing to navigate the health crisis caused by the COVID-19 pandemic and, to the best of our ability, fulfilling our responsibility to keep our colleagues and neighbors safe, we are advancing the important work of the Company, as expected, and ensuring the medications our patients depend on each day remain available to them without interruption. We are pleased that Sympazan continued its commercial growth during the second quarter. Also, in July 2020, the FDA accepted our IND for AQST-108, our drug candidate in development to deliver systemic epinephrine for the treatment of anaphylaxis, and we are progressing toward commencing our planned PK trials expected later in the third quarter of this year. Concurrently, we are continuing to advance through the FDA review process for our product candidate, Libervant™ (diazepam) Buccal Film for the management of seizure clusters, including providing information to the agency, responding to its information requests and working with the agency on its inspection of our manufacturing and clinical investigational sites. With the commercial foundation we have built for Sympazan, we will be prepared to launch Libervant quickly, if approved by the FDA for U.S. marketing access. The formal process for a potential monetization of our KYNMOBI royalty asset is ongoing.”Proprietary Pipeline Overview and Business Update Aquestive is building a portfolio of differentiated therapeutics that can offer physicians and patients, who have difficulty using currently available treatment options, improved clinical and usability features based on the Company’s PharmFilm® technology. The Company’s proprietary products and late-stage product candidates are initially focused on CNS conditions and other patient populations with high unmet need. * Aquestive submitted an Investigational New Drug (IND) application on June 26, 2020 to the U.S. Food and Drug Administration (FDA) for PK clinical trials of its drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive’s proprietary PharmFilm® technologies. As proposed by Aquestive and confirmed by the FDA at the pre-IND meeting held in February 2020, the clinical development for AQST-108 will be reviewed under the 505(b)(2) regulatory approval pathway. On July 23, 2020, Aquestive received confirmation from the FDA that the agency had completed its safety review of the IND and concluded that the Company could proceed with the first planned PK clinical trials of AQST-108. The Company expects to commence a crossover study to compare the pharmacokinetics and pharmacodynamics of epinephrine administered as sublingual film to that of epinephrine administered as an injection before the end of the third quarter of 2020. * Aquestive is engaging as expected with the FDA related to its New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters. The review to date has progressed with our providing information to the agency, responding to its information requests and working with the agency on its inspections of the Company’s manufacturing and clinical investigational sites. The Company expects that it will continue to have exchanges with the FDA as the September 27, 2020 Prescription Drug User Fee Act (PDUFA) goal date approaches. Aquestive is seeking to demonstrate to the FDA that Libervant will, if approved by the FDA for marketing in the U.S., represent a “major contribution to patient care” within the meaning of FDA regulations and guidance as compared to currently available treatment options, and further expand patient choice as the only orally delivered and non-device driven diazepam-based therapy available to manage seizure clusters in epilepsy patients. Although we cannot assure FDA approval of Libervant for U.S. marketing access, we remain committed to helping epilepsy patients affected by seizure clusters by working to bring innovative products to the market. * Sympazan® (clobazam), an oral film for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS) and launched as a precursor and complement to Libervant, continues to progress on key performance commercialization metrics including quarterly growth in retail shipments, number of prescribers, repeat prescribers, and covered lives, with the goal of helping prepare the market for a launch of Libervant, if approved by the FDA for marketing in the U.S. * KYNMOBI, an apomorphine thin film therapy for the treatment of off episodes in Parkinson’s disease patients, is licensed by the Company to Sunovion Pharmaceuticals, Inc. KNYMOBI received FDA approval on May 21, 2020. Under the terms of the license agreement with Sunovion, Aquestive is entitled to receive certain milestone payments and ongoing royalties on the world-wide net sales of KYNMOBI. The Company is in the process of seeking to monetize this asset. The formal process for a potential monetization of the Company’s KYNMOBI royalty asset is ongoing.Second Quarter 2020 Financials Total revenues were $21.7 million in the second quarter 2020, compared to $11.1 million in the second quarter 2019. This year-over-year increase reflected license fees and royalty revenue in the second quarter of 2020 primarily related to $12 million recognized as a result of the KYNMOBI approval, of which $8 million is non-cash revenue related to minimum royalties that will be received over future years. In addition, Aquestive saw revenue growth in the second quarter of 2020 compared to the prior year period of 59% for Sympazan, the first of its proprietary products to be launched, offset in part, by lower year-over-year performance of Suboxone®. Aquestive’s net loss for the second quarter 2020 was $2.3 million, or $0.07 loss per share. The net loss for the second quarter 2019 was $20.5 million, or $0.82 loss per share. The change in net loss was driven by higher revenue and reductions in costs and expenses, primarily in research and development and selling, general and administrative expenses in the second quarter 2020, compared to the second quarter 2019, partially offset by higher interest expense. Earnings before interest, taxes, depreciation and amortization, share-based compensation and other adjustments (adjusted EBITDA) was $2.9 million in the second quarter 2020, compared to $16.2 million of losses in the comparable prior period. The year-over-year change in adjusted EBITDA was driven primarily by higher revenue and reductions in costs and expenses, primarily in research and development and selling, general and administrative expenses in the second quarter 2020, compared to the second quarter 2019, partially offset by higher interest expense. As of June 30, 2020, cash and cash equivalents were $25.4 million. 2020 Outlook Aquestive is re-affirming its full year 2020 financial outlook. The Company’s full year guidance does not include the revenue recognized this quarter as a result of minimum royalty payments that will be received over future years from KYNMOBI.The Company expects: * Total revenues of approximately $35 million to $45 million * No Libervant revenues are included in the Company’s 2020 guidance * Non-GAAP adjusted gross margins of approximately 70% to 75% on total revenues * Non-GAAP adjusted EBITDA loss of approximately $45 million to $50 million * Cash burn of approximately $45 million to $50 millionThe novel coronavirus pandemic continues to evolve and the extent to which it may impact Aquestive’s ongoing and future business operations, financial results and resources, or the success of the Company’s commercial and candidate products, including Libervant, will depend on future developments which are uncertain. Tomorrow’s Conference Call and Webcast Reminder The Company will host a conference call at 8:00 a.m. ET on Wednesday, August 5, 2020. Investors and analysts may participate in the conference call by dialing (866) 417-5886 from the U.S. and (409) 217-8235 internationally, followed by the conference ID: 6069891.There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations. The webcast will be archived for 30 days.About Aquestive Therapeutics Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS and other conditions and provide alternatives to invasively administered standard of care therapies.
- 08/04/2020
|
The Daily Biotech Pulse: Voyager, AbbVie End Collaboration, Thumbs Down For DBV's Peanut Allergy Patch, Tiziana Expedites COVID-19 Trial Plans
- Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
ABIOMED, Inc. (NASDAQ: ABMD)
ALX Oncology Holdings Inc (NASDAQ: ALXO)
Annexon Inc (NASDAQ: ANNX)
Atossa...
- 08/04/2020
|
The Week Ahead In Biotech: Novavax Coronavirus Vaccine Readout, FDA Decisions And More Earnings
- Biotech stocks came under pressure in the week ended July 31 amid mixed earnings from the sector and some adverse clinical readouts.
COVID-19 news flow continued to pour in,...
- 08/02/2020
|
Aquestive Therapeutics to Present at 2020 Wedbush PacGrow Healthcare Virtual Conference
- WARREN, N.J., July 28, 2020 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference to be held August 11-12, 2020. Aquestive will present on August 11 at 9:45 am EDT and is available for one-on-one meetings during the conference. A webcast of the presentation will be available on the "Events and Presentations" page of the Investors section of the Company's website. A replay of each webcast will be available for 30 days following the event. For more information, please visit investors.aquestive.com.About Aquestive Therapeutics Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients. Aquestive is advancing a late-stage proprietary product pipeline to treat CNS conditions and provide alternatives to invasively administered standard of care therapies. The Company also collaborates with other pharmaceutical companies to bring new molecules to market using proprietary, best-in-class technologies, like PharmFilm®, and has proven capabilities for drug development and commercialization.Forward-Looking Statement This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include, but are not limited to, statements regarding therapeutic benefits and plans and objectives for regulatory approvals of AQST-108, LibervantTM and our other product candidates; ability to obtain FDA approval and advance AQST-108, Libervant and our other product candidates to the market, statements about our growth and future financial and operating results and financial position, regulatory approval and pathways, clinical trial timing and plans, our and our competitors’ orphan drug approval and resulting drug exclusivity for our products or products of our competitors, short-term and long-term liquidity and cash requirements, cash funding and cash burn, business strategies, market opportunities, and other statements that are not historical facts. These forward-looking statements are also subject to the uncertain impact of the COVID-19 global pandemic on our business including with respect to our clinical trials including site initiation, patient enrollment and timing and adequacy of clinical trials; on regulatory submissions and regulatory reviews and approvals of our product candidates; pharmaceutical ingredients and other raw materials supply chain, manufacture, and distribution; and sale of and demand for our products; our liquidity and availability of capital resources; customer demand for our products and services; customers’ ability to pay for goods and services; and ongoing availability of an appropriate labor force and skilled professionals. Given these uncertainties, the Company is unable to provide assurance that operations can be maintained as planned prior to the COVID-19 pandemic.These forward-looking statements are based on our current expectations and beliefs and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Such risks and uncertainties include, but are not limited to, risks associated with the Company's development work, including any delays or changes to the timing, cost and success of our product development activities and clinical trials and plans; risk of delays in FDA approval of Libervant and our other drug candidates or failure to receive approval; risk of our ability to demonstrate to the FDA “clinical superiority” within the meaning of the FDA regulations of our drug candidate Libervant relative to FDA-approved diazepam rectal gel and nasal spray products including by establishing a major contribution to patient care within the meaning of FDA regulations relative to the approved products as well as risks related to other potential pathways or positions which are or may in the future be advanced to the FDA to overcome the seven year orphan drug exclusivity granted by the FDA for the approved nasal spray product of a competitor in the U.S and there can be no assurance that we will be successful; risk that a competitor obtains FDA orphan drug exclusivity for a product with the same active moiety as any of our other drug products for which we are seeking FDA approval and that such earlier approved competitor orphan drug blocks such other product candidates in the U.S. for seven years for the same indication; risk inherent in commercializing a new product (including technology risks, financial risks, market risks and implementation risks and regulatory limitations); risks and uncertainties concerning potential monetization of royalty and other revenue stream of Apomorphine and of sufficiency of net proceeds of any such monetization after satisfaction of and compliance with 12.5% Senior Notes obligations as applicable; risk of development of our sales and marketing capabilities; risk of legal costs associated with and the outcome of our patent litigation challenging third party at risk generic sale of our proprietary products; risk of sufficient capital and cash resources, including access to available debt and equity financing and revenues from operations, to satisfy all of our short-term and longer term cash requirements and other cash needs, at the times and in the amounts needed; risk of failure to satisfy all financial and other debt covenants and of any default; risk related to government claims against Indivior for which we license, manufacture and sell Suboxone® and which accounts for the substantial part of our current operating revenues; risk associated with Indivior’s cessation of production of its authorized generic buprenorphine naloxone film product, including the impacts from loss of orders for the authorized generic product and risk of eroding market share for Suboxone and risk of sunsetting product; risks related to the outsourcing of certain sales, marketing and other operational and staff functions to third parties; risk of the rate and degree of market acceptance of our product and product candidates; the success of any competing products, including generics; risk of the size and growth of our product markets; risks of compliance with all FDA and other governmental and customer requirements for our manufacturing facilities; risks associated with intellectual property rights and infringement claims relating to the Company's products; risk of unexpected patent developments; the impact of existing and future legislation and regulatory provisions on product exclusivity; legislation or regulatory actions affecting pharmaceutical product pricing, reimbursement or access; claims and risks that may arise regarding the safety or efficacy of the Company's products and product candidates; risk of loss of significant customers; risks related to legal proceedings, including patent infringement, investigative and antitrust litigation matters; changes in government laws and regulations; risk of product recalls and withdrawals; uncertainties related to general economic, political, business, industry, regulatory and market conditions and other unusual items; and other uncertainties affecting the Company described in the “Risk Factors” section and in other sections included in our Annual Report on Form 10‑K, in our Quarterly Reports on Form 10-Q, and in our Current Reports on Form 8-K filed with the Securities Exchange Commission (SEC). Given those uncertainties, you should not place undue reliance on these forward-looking statements, which speak only as of the date made. All subsequent forward-looking statements attributable to us or any person acting on our behalf are expressly qualified in their entirety by this cautionary statement. The Company assumes no obligation to update forward-looking statements or outlook or guidance after the date of this press release whether as a result of new information, future events or otherwise, except as may be required by applicable law. PharmFilm® and the Aquestive logo are registered trademarks of Aquestive Therapeutics, Inc. All other registered trademarks referenced herein are the property of their respective owners.Investor inquiries: Stephanie Carrington stephanie.carrington@icrinc.com 646-277-1282
- 07/28/2020
|
Aquestive Therapeutics (AQST) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
- Aquestive Therapeutics (AQST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- 07/28/2020
|
Aquestive Therapeutics to Announce Second Quarter Financial Results and Recent Business Highlights on Aug 4 and Host Conference Call on Aug 5 at 8:00 a.m. ET
- WARREN, N.J., July 15, 2020 -- Aquestive Therapeutics, Inc. (NASDAQ: AQST), a pharmaceutical company focused on developing and commercializing differentiated products that.
- 07/15/2020
|
Aquestive Therapeutics (AQST) Receives a Buy from Wedbush - Markets
- In a report issued on July 10, Liana Moussatos from Wedbush maintained a Buy rating on Aquestive Therapeutics (AQST –
- 07/12/2020
|
What Is The Ownership Structure Like For Aquestive Therapeutics, Inc. (NASDAQ:AQST)?
- Every investor in Aquestive Therapeutics, Inc. (NASDAQ:AQST) should be aware of the most powerful shareholder groups...
- 07/06/2020
|
Aquestive Therapeutics (AQST) Receives a Buy from Wedbush - Markets
- Wedbush analyst Liana Moussatos reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report) today and set a price
- 06/30/2020
|
Aquestive Therapeutics (AQST) Receives a Buy from H.C. Wainwright - Markets
- H.C. Wainwright analyst Ram Selvaraju reiterated a Buy rating on Aquestive Therapeutics (AQST – Research Report) today and set a
- 06/30/2020
|
Aquestive Therapeutics Files IND for Pharmacokinetic Clinical Trials of AQST-108 (Sublingual Film Formulation Delivering Systemic Epinephrine) for Anaphylaxis Treatment
- Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for pharmacokinetic (PK) clinical trials of its drug candidate AQST-108, a “first of its kind” oral sublingual film formulation delivering systemic epinephrine that is in development for the treatment of anaphylaxis using Aquestive’s proprietary PharmFilm® technologies. The Company intends to initiate its planned PK trials before the year end 2020.
- 06/29/2020
|
Aquestive Therapeutics (AQST) Gets a Buy Rating from Wedbush - Markets
- In a report issued on June 26, Liana Moussatos from Wedbush maintained a Buy rating on Aquestive Therapeutics (AQST –
- 06/28/2020
|
Hedge Funds Aren’t Crazy About Aquestive Therapeutics, Inc. (AQST) Anymore
- At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW). In these volatile markets we scrutinize hedge fund filings to get a reading on which direction each […]
- 06/25/2020
|
Aquestive Therapeutics (AQST) Investor Presentation - Slideshow
- The following slide deck was published by Aquestive Therapeutics, Inc. in conjunction with this event.
- 06/23/2020
|
Aquestive Therapeutics (AQST) Gets a Buy Rating from Wedbush - Markets
- Wedbush analyst Liana Moussatos maintained a Buy rating on Aquestive Therapeutics (AQST – Research Report) on June 19 and set
- 06/22/2020
|
Aquestive Therapeutics to Present at BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference
- Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management will present at the BMO Capital Markets 2020 Prescriptions for Success Healthcare Conference to be held virtually on Tuesday, June 23, 2020. A webcast of the presentation will be available on the "Events and Presentations" page of the Investors section of the Company's website. Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients.
- 06/16/2020
|
Aquestive Therapeutics (AQST) Receives a Buy from Wedbush - Markets
- In a report issued on June 12, Liana Moussatos from Wedbush maintained a Buy rating on Aquestive Therapeutics (AQST –
- 06/14/2020
|
Aquestive Therapeutics to Hold Virtual-Only Annual Meeting of Stockholders
- Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that due to the public health and safety concerns related to the COVID-19 pandemic the location of its Annual Meeting of Stockholders has been changed to a virtual-only format, via live audio webcast. Stockholders will not be able to attend the Annual Meeting in person. The Company is modifying the meeting format due to the COVID-19 pandemic and will determine whether future Annual Meetings will be hosted in-person or via a virtual format depending on future health concerns.
- 06/04/2020
|
Implied Volatility Surging for Aquestive Therapeutics (AQST) Stock Options
- Investors need to pay close attention to Aquestive Therapeutics (AQST) stock based on the movements in the options market lately.
- 05/28/2020
|
Why Aquestive Therapeutics (AQST) Stock Might be a Great Pick
- Aquestive Therapeutics (AQST) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
- 05/27/2020
|
The Daily Biotech Pulse: FDA Nod For Aquestive, Tetraphase M&A Plot Thickens, Amarin's Vascepa In COVID Fray
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 21) * ADC Therapeutics SA (NYSE: ADCT) (IPOed May 15) * Allogene Therapeutics Inc (NASDAQ: ALLO) * AstraZeneca plc (NYSE: AZN) ( announced $1 billion BARDA funding for coronavirus vaccine program) * Biondvax Pharmaceuticals Ltd - ADR (NASDAQ: BVXV) * Cellectis SA (NASDAQ: CLLS) * ChemoCentryx Inc (NASDAQ: CCXI) * Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) * Cue Biopharma Inc (NASDAQ: CUE) * Fate Therapeutics Inc (NASDAQ: FATE) * Harpoon Therapeutics Inc (NASDAQ: HARP) * Horizon Therapeutics PLC (NASDAQ: HZNP) * Intellia Therapeutics Inc (NASDAQ: NTLA) * Kamada Ltd. (NASDAQ: KMDA) * Minerva Neurosciences Inc (NASDAQ: NERV) * Ovid Therapeutics Inc (NASDAQ: OVID) * Passage Bio Inc (NASDAQ: PASG)(FDA granted Rare Pediatric Disease designation to its gene therapy PBGM01 broadly for the treatment of GM1 gangliosidosis) * Soleno Therapeutics Inc (NASDAQ: SLNO) * Surface Oncology Inc (NASDAQ: SURF)Down In The Dumps (Biotech Stocks Hitting 52-week Lows May 21) * Akorn, Inc. (NASDAQ: AKRX) (filed for Chapter 11 bankruptcy) * Digirad Corporation (NASDAQ: DRAD) * Genfit SA (NASDAQ: GNFT)Related Link: These 6 Coronavirus Vaccine Candidates Are The Likeliest To Succeed, Says Morgan StanleyStocks In Focus Aquestive's Partnered Parkinson's Drug Gets FDA Nod Aquestive Therapeutics Inc's (NASDAQ: AQST) development partner Sunovion announced FDA approval for Kynmobi sublingual film - APL-130277 - for the acute, intermittent treatment of OFF episodes in patients with Parkinson's disease. The drug is expected to be available in the U.S. pharmacies in September.Following the approval, Aquestive said it plans to monetize its PharmFilm based therapies."We continue to expect that we will receive between $50 to $100 million of non-dilutive capital from the monetization, in one or a series of transactions," the company said.The stock rose 5.2% to $6.47 in after-hours trading.Syndax's Lead Breast Cancer Drug Flunks Late-stage Study Syndax Pharmaceuticals Inc (NASDAQ: SNDX) said a late-stage study that evaluated its investigational compound entinostat along with exemestane in patients with HR+, HER2- breast cancer who have progressed on a non-steroidal aromatase inhibitor did not achieve the primary endpoint of demonstrating a statistically significant overall survival benefit over hormone therapy alone.The study was conducted by ECOG-ACRIN Cancer Research Group and sponsored by the National Cancer Institute.The stock slumped 19.41% to $16.52 in after-hours trading.Tiziana To Spin-off Its Personalized Medicines Businesses TIZIANA LF SCIE/S ADR (NASDAQ: TLSA) said it intends to demerge its StemPrintER and SPARE genomics-based personalized medicine businesses into a separate company and effect a capital reduction to facilitate the spin-out and listing of StemPrintER as an independent entity.Amarin To Support Pilot Study Of Vascepa In Treating COVID-19 Amarin Corporation plc (NASDAQ: AMRN) said it supports a clinical trial to investigate the effects of its Vascepa on inflammatory biomarkers and other patient outcomes in individuals with COVID-19. The trial is sponsored by the Canadian Medical and Surgical Knowledge Translation Research Group, the company said.Separately, generic pharma company Hikma Pharmaceuticals announced its wholly-owned U.S. subsidiary Hikma Pharmaceuticals USA Inc. has received FDA approval for its generic equivalent to Vascepa.In pre-market trading Friday, Amarin stock was adding 3.85% to $7.56.Navidea Reports Positive Mid-stage Results For Rheumatoid Arthritis Treatment Navidea Biopharmaceuticals Inc (NYSE: NAVB) announced positive preliminary results from the second interim analysis of its ongoing NAV3-31 Phase 2B study"Analysis demonstrates that these interim data further corroborate Navidea's hypotheses that Tc99m tilmanocept imaging can provide robust, quantitative imaging in healthy controls and in patients with active rheumatoid arthritis, and that this imaging can provide an early indicator of treatment efficacy in patients with active RA," the company said.The stock was seen skyrocketing 65.35% to $2.10 in pre-market trading.Roche Buys Gene Sequencing Tech Company Roche Holdings AG (OTC: RHHBY) announced acquisition of Stratos Genomics, an early-stage sequencing technology company to advance the development of its nanopore sequencer.The company did not disclose the financial terms of the dealTetraphase Deems Melinta's Latest All-Cash Offer As Superior, Notifies AcelRx Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH), which has been pursued by multiple companies, said its board has determined that the latest proposal from Melinta Therapeutics, Inc. is a "Superior Offer."'Melinta has offered $27 million in cash, plus an additional $12.5 million in cash potentially payable under contingent value rights to be issued in the proposed acquisition.View more earnings on IBBTetraphase, which agreed to a deal to be bought byAcelRx Pharmaceuticals Inc (NASDAQ: ACRX), said it has informed about its determination concerning the Melinta offer and given AcelRx time until May 29 to either terminate the merger or revise the terms of the merger.Incidentally, La Jolla Pharmaceutical Company (NASDAQ: LJPC) had also tabled an offer for Tetraphase.In pre-market trading, AcelRx shares were adding 2.74% to $1.50.Amag Divests Intrarosa For Upto $125M AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) said it has completed the sale of its rights to Intrarosa to Millicent Pharma Limited, for up to $125 million, including upfront fixed consideration of $20 million and contingent, sales-based milestone payments of up to $105 million.The company said the sale is consistent with its previously announced strategic decision to divest its women's health assets. It also said it remains committed to the divestiture of Vyleesi and associated expense reductions as previously announced.Offerings ContraFect Corp Stock (NASDAQ: CFRX) said it has priced its underwritten public offering of 11.8 million shares of its common stock and related warrants to purchase 8.85 million shares. The gross proceeds from the public offering will be approximately $52.5 million, it said. All shares in the public offering are to be sold by ContraFect.In premarket trading Friday, the stock was slipping 11.87% to $4.75.Hoth Therapeutics Inc (NASDAQ: HOTH) priced its underwritten public offering of 1.82 million shares of common stock at $2.75 per share, for raising gross proceeds of $5 million. The offering is expected to close on or about May 27.The stock was slipping 5.36% to $3 in premarket trading Friday.Dynavax Technologies Corporation (NASDAQ: DVAX) priced its previously announced underwritten public offering of 14 million shares of its common stock at $5 per share. The gross proceeds to Dynavax from the offering are expected to be approximately $70. The offering is expected to close on or about May 27.The stock was retreating 10.25% to $5.08 in premarket trading Friday.PPD Inc (NASDAQ: PPD) said it upsized and finalized the terms of the offering of $500 million aggregate principal amount of 4.625% senior notes due 2025 and $700 million aggregate principal amount 5.000% senior notes due 2028. The aggregate principal amount of the notes to be issued in the offering was increased to $1.2 billion from the previously announced $700 million, the company said.In premarket trading Friday, the stock was adding 1.23% to $28.Geron Corporation (NASDAQ: GERN) said it intends to offer and sell shares of its common stock and accompanying warrants to purchase shares of its common stock in an underwritten public offering. All the securities earmarked for the offering are being sold by the company.The stock was slipping 20.92% to $1.55 in pre-market trading.On The Radar Clinical Readouts Atara Biotherapeutics Inc's (NASDAQ: ATRA) abstract on the Phase 1 data for ATA188 in multiple sclerosis, regarding its European Academy for Neurology presentation, will be made available online at 12:30 pm ET.Earnings Teligent Inc (NEW JERSEY) (NASDAQ: TLGT)IPO Inari Medical, a medical device company, priced its upsized initial public offering of 8.203 million shares of its common stock at $19.00 per share, for total gross proceeds of approximately $156 million. The company had earlier planned for a 7.33-million stock offering, with an estimated price of $17-$18 per share. The shares are to be listed on the Nasdaq under the ticker symbol NARI.See more from Benzinga * The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive * The Daily Biotech Pulse: Aldeyra Jumps Into COVID-19 Drug Fray, FDA Nod For Myriad's Companion Diagnostic Test * The Daily Biotech Pulse: FDA Nod For Roche, Arbutus Releases Positive Readout For HBV Therapy, Moderna Announces .34B Common Stock Offering(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/22/2020
|
Aquestive Therapeutics Advances Royalty Monetization Plan as Sunovion Pharmaceuticals’ Apomorphine Sublingual Film Therapy Receives FDA Approval
- Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced plans to advance its strategy to monetize the anticipated royalties associated with Sunovion Pharmaceuticals’ apomorphine sublingual film APL-130277, which received FDA approval to treat motor fluctuations (OFF episodes) experienced by people living with Parkinson’s disease. As disclosed in Aquestive’s filings with the SEC, in April 2016, Aquestive entered into a license agreement with Cynapsus Therapeutics (which was later succeeded to in interest by Sunovion), pursuant to which Aquestive granted Sunovion an exclusive, worldwide license (with the right to sub-license) to certain intellectual property, including existing and future patents and patent applications, covering all oral films containing APL-130277 (apomorphine) for the treatment of motor fluctuations (OFF episodes) in Parkinson’s disease patients, as well as two other therapeutic fields.
- 05/21/2020
|
The Daily Biotech Pulse: Mixed Filgotinib Readout For Gilead-Galapagos, Akorn To File For Chapter 11, D-Day For Aquestive
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs on May 20.)
ADC Therapeutics SA (...
- 05/21/2020
|
Is Aquestive Therapeutics (AQST) Outperforming Other Medical Stocks This Year?
- Is (AQST) Outperforming Other Medical Stocks This Year?
- 05/20/2020
|
The Week Ahead In Biotech: Aquestive Awaits FDA Decision, Earnings Flow Slows
- Biotech stocks had another up week, with the American Society of Gene & Stem Cell Therapy virtual conference presentations and the ASCO abstracts made available online ...
- 05/17/2020
|
Aquestive Therapeutics' Shares March Higher, Can It Continue?
- As of late, it has definitely been a great time to be an investor in Aquestive Therapeutics.
- 05/14/2020
|
All You Need to Know About Aquestive Therapeutics (AQST) Rating Upgrade to Buy
- Aquestive Therapeutics (AQST) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- 05/12/2020
|
Publicly-traded companies blasted for taking small business loans. Those from N.J. got $32M.
- The companies, however, returned 2/3 of the loans they received under the paycheck protection program.
- 05/10/2020
|
Aquestive Therapeutics, Inc. (AQST) CEO Keith Kendall on Q1 2020 Results - Earnings Call Transcript
- Aquestive Therapeutics, Inc. (NYSE:HEI) Q1 2020 Earnings Conference Call May 07, 2020, 08:00 AM ET Company Participants Stephanie Carrington - Westwicke, IR Kei
- 05/10/2020
|
Benzinga Pro's Top 5 Stocks To Watch For Fri., May 8, 2020: KC, IDXX, LAZY, AQST, AN
- Today's 5 Stock Ideas: * Kingsoft Cloud (KC) \- A new issue expected to open Friday morning. The company is one of China's top cloud service providers. Shares were expected in the $16-$18/share range and priced right in the middle at $17/share. * IDEXX (IDXX) \- A play on coronavirus testing. The company reported its OPTI Medical subsidiary was granted FDA Emergency Use Authorization for OPTI coronavirus lab test kit. * Lazydays (LAZY) \- A play on the RV market. Public health workers and nurses have recently used RVs as a way to effectively separate their home environment from their families. * Aquestive Therapeutics (AQST) \- A play on an upcoming FDA date. The company is expected see an FDA PDUFA action date for its Parkinson's treatment New Drug Application within the next two weeks. * AutoNation (AN) - An earnings play. The company will report quarterly results before the market open on Monday.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Fri., Apr. 3, 2020: USIO, NTDOY, AJRD, AN, OTIS(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
- 05/08/2020
|
Aquestive Therapeutics to Present at 2020 RBC Capital Markets Global Healthcare Conference
- Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that management will present at the 2020 RBC Capital Markets Global Healthcare Conference to be held virtually on May 19-20. A webcast of the presentation will be available on the "Events and Presentation" page of the Investors section of the Company's website. Aquestive Therapeutics is a pharmaceutical company that applies innovative technology to solve therapeutic problems and improve medicines for patients.
- 05/07/2020
|
Aquestive Therapeutics, Inc. (AQST) Q1 2020 Earnings Call Transcript
- Good morning, and welcome to today's call to review Aquestive Therapeutics' results for the first quarter of 2020 and business highlights. On today's call I am joined by Keith Kendall, President and Chief Executive Officer; and John Maxwell, Chief Financial Officer, who are going to provide an overview of the recent business developments and performance in the first quarter.
- 05/06/2020
|
Aquestive Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Update: AQST-108 and Libervant Remain On Track
- Continues to manufacture and deliver therapies and advance R&D; efforts during COVID-19 pandemic Expects to submit AQST-108 (epinephrine) IND by June 2020 and to commence PK.
- 05/05/2020
|
The Daily Biotech Pulse: Bio-Rad's Coronavirus Test Gets EUA, Beat-And-Raise Quarter From GenMark, Adverum's Positive Gene Therapy Readout
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 5.)
Arcturus Therapeutics Ltd (...
- 05/05/2020
|
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
- Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
- 05/03/2020
|
Coronavirus Economy: SBA Paycheck Program Awarded $1 Billion To Publicly Traded Companies
- Some of the loans were for many times the $10 million limit; some went to companies with more than 500 employees.
- 05/01/2020
|
Aquestive Therapeutics (AQST) Receives a Buy from H.C. Wainwright
- In a report released today,
Ram Selvaraju
from H.C. Wainwright reiterated a
Buy
rating on Aquestive Therapeutics (
AQST
–
Research Report
), with a price target of
$13.00
. The company’s shares closed last Friday at $3.55.
According to
TipRanks.com
,
- 04/27/2020
|
3 Biotech Stocks Under $4 With Big Upside Potential
- At the very moment it looked like the market was down for the count, stocks bounced back. After being dealt hefty blows earlier in the week due to the record-breaking drop in oil prices, all three of the major U.S. stock indexes rallied on Friday April 24. The surge was supported by rising crude prices
- 04/26/2020
|
Treasury urges publicly traded companies to return PPP loans
- Following objections over large publicly traded companies getting forgivable loans under the Payroll Protection Program, the U.S. Treasury issues new guidance explaining that the program is meant for
- 04/23/2020
|
Publicly-traded companies raided the PPP pantry
- Even with the U.S. Senate set to vote later today on passing an additional relief bill for small businesses in the U.S., there is a bright spotlight being thrown on where the funds from the original
- 04/21/2020
|
Aquestive Therapeutics to Announce First Quarter Financial Results and Recent Business Highlights on May 5 and Host Investment Community Conference Call on May 6
- Aquestive Therapeutics, Inc. (AQST), a pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that it will report results for the first quarter ended March 31, 2020 and provide a business update after market close on Tuesday, May 5, 2020. The Company will host an investment community conference call at 8:00 a.m. ET on Wednesday, May 6, 2020. There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations.
- 04/21/2020
|
H.C. Wainwright Sticks to Its Buy Rating for Aquestive Therapeutics (AQST)
- In a report released today,
Ram Selvaraju
from H.C. Wainwright reiterated a
Buy
rating on Aquestive Therapeutics (
AQST
–
Research Report
), with a price target of
$13.00
. The company’s shares closed last Monday at $3.60.
According to
TipRanks.com
,
- 04/21/2020
|
ROKU, CCL among premarket gainers today
- Sonnet BioTherapeutics Holdings (NASDAQ:SONN) +100%.MEI Pharma (NASDAQ:MEIP) +71% on license deal for blood cancer candidate.NantKwest (NASDAQ:NK) +39% being with ImmunityBio on active discussions wit
- 04/14/2020
|
Top Ranked Momentum Stocks to Buy for April 14th
- Top Ranked Momentum Stocks to Buy for April 14th
- 04/14/2020
|
Top Ranked Momentum Stocks to Buy for April 14th
- Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, April 14th
- 04/14/2020
|
Aquestive Therapeutics (AQST) Receives a Buy from RBC Capital
- In a report released today,
Randall Stanicky
from RBC Capital reiterated a
Buy
rating on Aquestive Therapeutics (
AQST
–
Research Report
), with a price target of
$8.00
. The company’s shares closed last Monday at $1.89, close to its 52-week low of $
- 03/25/2020
|
The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 16.) * BioNTech SE - ADR (NASDAQ: BNTX) (announced efforts to develop a vaccine for COVID-19) * SUMMIT THERAPEU/S ADR (NASDAQ: SMMT)Down In The Dumps
- 03/17/2020
|
Memgen Appoints Gregory Brown as Chief Executive Officer
- Company founder Robert Coates becomes Executive Chairman Houston, Texas--(Newsfile Corp. - March 17, 2020) - Memgen, a private biotechnology company developing innovative immuno-oncology drugs, announced today that its Board of Directors has appointed Gregory B. Brown, MD, as Chief Executive Officer. He currently serves and will remain on the Memgen board of directors. The company also announced that Robert Coates, PhD, founder and prior Chief Executive Officer, will become Executive Chairman."Having seen the scientific capability ...
- 03/17/2020
|
Wall Street Analysts Are Bullish on Top Healthcare Picks
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aquestive Therapeutics (AQST) and Verastem (VSTM) with
- 03/16/2020
|
Aquestive Therapeutics, Inc. Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
- There's been a major selloff in Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares in the week since it released its...
- 03/14/2020
|
Company News for Mar 13, 2020
- Companies In The News Are: POAI, APT, AQST, TACO
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 12.) * Masimo Corporation (NASDAQ: MASI)Down In The Dumps (Biotech stocks that hit 52-week lows March 12.) * Abbott Laboratories (NYSE: ABT) * ABIOMED
- 03/13/2020
|
The Daily Biotech Pulse: Roche Obtains FDA Emergency Use Authorization For COVID-19 Test, Chembio Appoints New CEO, Inovio Slumps On Earnings
- Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks that hit 52-week highs March 12.)
Masimo...
- 03/13/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week highs on March 11) * Bicycle Therapeutics PLC (NASDAQ: BCYC) (reacted to its fourth-quarter results) * Centogene NV (NASDAQ: CNTG) * Tiziana Life Sciences PLC (NASDAQ
- 03/12/2020
|
The Daily Biotech Pulse: AstraZeneca Faces Setback In Ovarian Cancer Study, Mallinckrodt To Explore COVID-19 Treatment, Imara IPO
- Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week highs on March 11)
Bicycle Therapeutics...
- 03/12/2020
|
Aquestive Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights
- Expects to submit IND application for AQST-108 (epinephrine) in second quarter 2020 and commence pharmacokinetics (PK) clinical trials before end of 2020FDA sets Libervant™.
- 03/11/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.The week was light on news flow, barring some smid-cap earnings and COVID-19 treatment and vaccine news. View more earnings on IBBThe following are key catalysts in the unfolding week that a biotech
- 03/08/2020
|
The Week Ahead In Biotech (March 8-14): Bristol-Myers Awaits FDA Nod For Liver Cancer Combo Therapy, Earnings Flow Continues
- Biotech stocks rebounded in the week ended March 6, recovering from the previous week's steep sell-off.
The week was light on news flow, barring some smid-cap earnings and...
- 03/08/2020
|
7 Cheap Stocks Under $7 With Massive Upside Potential
- Cheap stocks - that is, really cheap stocks that trade for single-digit prices - are among the most divisive stocks on Wall Street.Some investors tend to avoid these names entirely. While nominal prices typically don't matter (there's little difference between a $50 stock and a $500 stock), stocks under $10 are different. They often face some sort of difficulty, such as weak fundamentals or overwhelming headwinds. Also, institutional buyers such as pensions and hedge funds often won't buy stocks that are cheaper than $10, and they really become sparse under the $5 mark. Thus, these companies miss out on the steadiness that accompanies institutional ownership.But other investors love cheap stocks. In many cases, they see opportunity in these often battered shares, and some people simply prefer to buy their stocks in "lots" (typically 100 shares at a time) - something that's a little more difficult to do with the triple- and quadruple-digit crowd.The reality is, low-priced stocks are a mix of high-return opportunity but also high risk. The crazy volatility introduced by the coronavirus outbreak certainly doesn't help. Further complicating things is that many of them are largely ignored by the media, making information difficult to come by. So if you are going to take a moonshot, take a cue from the pros that routinely cover these companies.Here are seven of the best cheap stocks under $7. Using TipRanks' Stock Screener tool, we identified seven low-priced stocks that still have decent Wall Street analyst coverage and extremely bullish sentiment. Note that every one of these stocks still comes with colossal risk. But if you're looking to get aggressive and buy cheap on dips, the pros think each of these can offer some promise. SEE ALSO: 13 Super Small-Cap Stocks to Buy for 2020 and Beyond
- 03/03/2020
|
Head-To-Head Analysis: Apellis Pharmaceuticals (NASDAQ:APLS) versus Aquestive Therapeutics (NASDAQ:AQST)
- Apellis Pharmaceuticals (NASDAQ:APLS) and Aquestive Therapeutics (NASDAQ:AQST) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, profitability, dividends, risk, valuation, earnings and institutional ownership. Risk and Volatility Apellis Pharmaceuticals has a beta of 0.6, meaning that its stock price is […]
- 02/23/2020
|
Aquestive Therapeutics to Announce Fourth Quarter and Full Year 2019 Financial Results and Recent Business Highlights on March 12, 2020
- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, today announced that it will report results for the fourth quarter and full year ended December 31, 2019 and provide a business update on Thursday, March 12, 2020 before the market open. The Company will host an investment community conference call at 8:00 a.m. ET on Thursday, March 12, 2020. There will also be a simultaneous, live webcast available on the Investors section of the Company’s website at https://investors.aquestive.com/events-and-presentations.
- 02/20/2020
|
Analysts Offer Insights on Healthcare Companies: Myovant Sciences (MYOV) and Aquestive Therapeutics (AQST)
- There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Myovant Sciences (MYOV) and Aquestive Therapeutics (AQST)
- 02/10/2020
|
Analysts Offer Insights on Healthcare Companies: Myovant Sciences (NYSE: MYOV) and Aquestive Therapeutics (NASDAQ: AQST)
- There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Myovant Sciences (
MYOV
–
Research Report
) and Aquestive Therapeutics (
AQST
–
Research Report
) with bullish sentiments.
Myovant Sciences (MYOV)
Cowen &
- 02/10/2020
|
TSLA, INO among premarket gainers
- vTv Therapeutics (NASDAQ:VTVT) +80% on positive TTP399 data.Taubman Centers (NYSE:TCO) +52% on being acquired by Simon Property Group.Edgewell Personal Care (NYSE:EPC) +21% after Q4 results.Mereo BioP
- 02/10/2020
|
Aquestive Therapeutics Announces U.S. Food and Drug Administration Filing Acceptance of New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film
- Aquestive Therapeutics, Inc. (AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products that address patients’ unmet needs and solve therapeutic problems, announced today that, as anticipated, the U.S. Food and Drug Administration (FDA) accepted the Company’s New Drug Application (NDA) for Libervant™ (diazepam) Buccal Film for the management of seizure clusters. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) goal date of September 27, 2020.
- 02/10/2020
|
TWTR, ZNGA among premarket gainers
- Unisys (NYSE:UIS) +39% as Unisys federal unit being acquired by Science Applications International.Myomo (NYSEMKT:MYO) +32%.China Xiangtai Food (NASDAQ:PLIN) +26% on announcing 300% supermarket sales
- 02/06/2020
|
Ten new option listings and two option delistings on January 23rd AKRO;AQST;CYCN;ITRN;OBSV;PHAS;PHAT;STOK;XP;MDR;TOO
- Ten new option listings and two option delistings on January 23rd AKRO AQST CYCN ITRN OBSV PHAS PHAT STOK XP MDR TOO
- 01/23/2020
|
Mid-Morning Market Update: Markets Open Higher; Cott To Acquire Primo Water
- Following the market opening Monday, the Dow traded up 0.07% to 28,844.56 while the NASDAQ rose 0.38% to 9,213.47. The S&P also rose, gaining 0.26% to 3,273.88.
Leading and...
- 01/13/2020
|
